Lixian Peng

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer

Kim N., Jennifer L. Spratlin, Christian Kollmannsberger et al. · The Journal of Clinical Pharmacology · 2015 · 104 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

Sumanta K. Pal, Javier Puente, Daniel Yick Chin Heng et al. · European Urology · 2022 · 27 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · Journal of Clinical Oncology · 2019 · 24 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +13

Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

Sumanta K. Pal, Javier Puente, Daniel Yick Chin Heng et al. · Journal of Clinical Oncology · 2021 · 11 citations

Medicine, Oncology, Pharmacotherapy +17